Constipation or diarrhea may also appear
Tirzepatide, a groundbreaking dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has set a new standard in the treatment of type 2 diabetes (T2DM) and obesity. As one of the most effective GLP-1 receptor agonists (GLP-1RAs), tirzepatide has demonstrated superior efficacy in reducing HbA1c levels (-2.10%) and fasting plasma glucose concentrations (-3.12 mmol/L), offering unmatched glycemic control. It also provides significant benefits in weight management, with an average reduction of -8.47 kg, making it a powerful tool for addressing the ""twin epidemics"" of diabetes and obesity. Approved by the FDA under the brand name Mounjaro, tirzepatide uses innovative acylation technology to extend its half-life, allowing for once-weekly subcutaneous injections
Research proposes that while it may influence senescence-associated pathways, it appears to preserve FOXO4s antioxidative transcriptional activity
High activity levels help counteract metabolic adaptation
The bottom line GLP-1 drugs do not reduce fat despite insulin
Fortunately, these side effects tend to be mild and can often be managed effectively with some lifestyle changes or over-the-counter remedies
